Alcon has Vexol (a corticosteroid) listed on their pipeline as a probably FDA submission for 2009 and it appears in at least one clinical trial database as being in Phase II. I assume this is their answer to the current trend of attacking inflammation (or at least B&L's aggressive Lotemax campaigns).
I haven't heard a PEEP about Rebamipide in ages. Hey Novartis, what gives?
I'm now showing a total of 7 dry eye drugs in Phase III, another 7 in Phase II, and 9 in earlier development. Presumably something somewhere in all this melee is going to turn out really useful.
No comments:
Post a Comment